Poniard Pharmaceuticals, Inc. (PARD)

[john wayne]

This was posted by Serf in November:

7:05AM Poniard Pharma announces Ph. 3 SPEAR trial of picoplatin in SCLC did not meet primary endpoint (PARD) 7.58 : Co announces that its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer did not meet its primary endpoint of overall survival. The analysis, based on 320 evaluable events (patient deaths), showed a hazard ratio of 0.82 with a p value of 0.089. Co will host conf. call at 8:00 AM EST to discuss announcement.